SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention as investors await the 80th event in its REGAL Phase 3 trial, the trigger for final analysis; the companys last disclosed count was 78. Bulls interpret the prolonged wait and a reflective CEO anniversary post as possible signs of longer survival or upcoming ASH data, while skeptics say neither the trial outcome nor a near-term disclosure is confirmed.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is drawing attention after reporting a quarterly adjusted-EBITDA beat and projecting stronger performance, with traders pointing to higher steel prices and signed contracts. Bulls see potential for short covering, while skeptics question whether price assumptions and the companys debt can support the outlook.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a sharp selloff across AI neocloud stocks, as concerns about financing costs, debt exposure and the durability of AI infrastructure spending weigh on the sector. Traders are split between viewing the decline as an oversold buying opportunityciting Nebiuss comparatively stronger balance sheet and insider purchasesand expecting further losses amid the broader reassessment of neocloud business models.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

WULF is drawing attention amid a sharp selloff across AI-data-center and crypto-mining stocks, as traders debate financing costs, leverage and the outlook for AI infrastructure after Gartners spending-risk warning and hotter inflation revived rate concerns. Bulls argue TeraWulfs powered-shell, contracted-lease model sets it apart from GPU-owning peers and view the decline as excessive; bears worry the sectors funding pressures could keep weighing on shares.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is drawing attention after a sharp price and volume surge, with traders debating whether the move marks a sustained breakout or another short-lived pump that could fade. Some speculate about renewed interest in Flexa, its relationship with ANVL, or broader altcoin momentum, but no specific catalyst is confirmed.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

AAOIs sharp selloff has focused attention on dilution and capital-raising concerns tied to its ATM share offering, alongside weakness across AI and optical-networking stocks and a cited B. Riley target cut. Traders are split between seeing the pullback as a buying opportunity on continued AI-transceiver demand and fearing further losses due to financing needs and execution risks.

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

AMAT is drawing attention after a sharp slide alongside AI-linked and semiconductor stocks, as inflation concerns and doubts about the durability of AI investment weigh on the sector. Traders are debating whether the steep decline has made shares oversold and worth buying or signals more downside; some also point to uncertainty after management offered no near-term wafer-fab equipment spending forecast at its investor presentation.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

Renewed takeover speculation is driving attention, with traders discussing an unconfirmed report that a West Coast technology company may be considering an all-stock offer after earlier Stripe talks stalled. Many speculate Meta could be the bidder, while others question the rumors credibility and warn the move may be rumor-driven rather than a confirmed deal.

Curaleaf Holdings, Inc. operates as a holding company with interest in medical and wellness cannabis operations. It operates through the Domestic Operations and International Operations segments. The company was founded on November 13, 2014 and is headquartered in Stamford, CT.

Curaleaf Holdings Inc

Curaleafs enhanced hostile bid for Aurora and Auroras continued rejection are the main focus, with traders divided over the deals value and whether the acquisition could build a larger international cannabis business or strain Curaleaf through dilution. Some also point to delays in federal rescheduling as a drag on cannabis stocks amid CURLFs decline.

VS Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

A sharp volatility spike, with traders pointing to risk-off pressure in tech, rising oil and Treasury yields, and possible geopolitical escalation, has driven attention to UVIX. Some welcome the surge as a hedge or short-term trade, while others warn that futures contango and the funds built-in decay can quickly reverse gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400

Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400 Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400PR NewswireBOULDER, Colo., Oct. 8, 2026 Phase 2 trial evaluating EDG-15400 in adults with symptomatic HFpEF with a LVEF of at...

Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?

Bristol Myers' Camzyos gains a broader FDA label and strong sales growth, while emerging competitors and pipeline setbacks shape its cardiovascular outlook.

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPR NewswireBOULDER, Colo., Oct. 1, 2026BOULDER, Colo., Oct. 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc...

Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500

Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500 Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500PR NewswireBOULDER, Colo., Sept. 22, 2026 - TheMoA that...

Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook? 

Bristol Myers??? Camzyos delivers durable five-year benefits, rising sales and potential adolescent label expansion.

Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?

Cytokinetics' aficamten shows added benefits in HCM studies, strengthening its potential in non-obstructive and obstructive disease.

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire BOULDER, Colo., Sept. 2, 2026 BOULDER, Colo., Sept. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc...

Can Camzyos' Growth Offset Bristol Myers' Patent Pressures?

BMY's Camzyos gains momentum as an adolescent expansion nears an FDA decision, while rivals advance competing heart drugs.

Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026

Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026 Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026 PR Newswire BOULDER, Colo...

Edgewise Therapeutics Reports Second Quarter 2026 Financial Results

Edgewise Therapeutics Reports Second Quarter 2026 Financial Results Edgewise Therapeutics Reports Second Quarter 2026 Financial Results PR Newswire BOULDER, Colo., Aug. 6, 2026 Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive...

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

Edgewise Therapeutics Inc

EWTX Stock Hits Record High – Why Servier Is Shelling Out $2.65B For Edgewise’s Muscular Dystrophy Business

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$37.19
Prev Close	$38.20
Open	$38.28
Dividend Yield	0.00%
50-Day Moving Average	$42.29
Beta	1.45
Avg. Volume	1.64M
PE Ratio	-20.11

52-Week High	$48.51
52-Week Low	$14.68
Market Capitalization	$4.04B
EPS (Annual)	-$1.63
Price to Book	8.95
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

EWTX Fundamentals